Spectrum Pharmaceuticals, Inc. (SPPI): Price and Financial Metrics


Spectrum Pharmaceuticals, Inc. (SPPI): $0.44

0.01 (+3.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SPPI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SPPI Stock Price Chart Interactive Chart >

Price chart for SPPI

SPPI Price/Volume Stats

Current price $0.44 52-week high $2.45
Prev. close $0.43 52-week low $0.41
Day low $0.42 Volume 1,863,500
Day high $0.45 Avg. volume 3,897,523
50-day MA $0.99 Dividend yield N/A
200-day MA $0.94 Market Cap 82.59M

Spectrum Pharmaceuticals, Inc. (SPPI) Company Bio


Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. The company was founded in 1987 and is based in Henderson, Nevada.


SPPI Latest News Stream


Event/Time News Detail
Loading, please wait...

SPPI Latest Social Stream


Loading social stream, please wait...

View Full SPPI Social Stream

Latest SPPI News From Around the Web

Below are the latest news stories about SPECTRUM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SPPI as an investment opportunity.

Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug

The FDA Oncologic Drugs Advisory Committee votes against Spectrum's (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations. Stock down.

Yahoo | September 26, 2022

B.Riley Financial Sticks to Their Buy Rating for Spectrum Pharmaceuticals (SPPI)

In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Spectrum Pharmaceuticals (SPPI - Research Report), with a price target of $1.50. The company's shares closed yesterday at $0.63.Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Novavax, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -28.8% and a 20.34% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spectrum Pharmaceuticals with a $4.83 average price target, which is a 661.47% upside from current levels.

Howard Kim on TipRanks | September 23, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're breaking down the biggest pre-market stock movers for Friday morning alongside the news that traders need to know about!

William White on InvestorPlace | September 23, 2022

Despite Regulatory Setback, Spectrum Still "Unique Investment Opportunity," Says Analyst

Yesterday, the FDA's Oncologic Drugs Advisory Committee (ODAC) panel voted against Spectrum Pharmaceuticals Inc's (NASDAQ: SPPI) poziotinib's (pozi) risk/benefit ratio and concluded that pozi's benefits do not outweigh the risks for the treatment of HER2 exon 20 insertion mutations. Meanwhile, with a newly approved commercial product Rolvedon launching into the $2.3 billion G-CSF space, JMP Securities believes that Spectrum shares still represent a unique investment opportunity with a 34% potent

Yahoo | September 23, 2022

After Regulatory Setback, Spectrum Pharma Secures Up To $65M In Debt Funding

Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) entered into a five-year debt financing agreement with SLR Capital Partners for a term loan facility of up to $65 million. The company believes this transaction, combined with Spectrum's existing cash balance of $68 million as of June 30, provides sufficient capital to optimize the commercial launch of Rolvedon (eflapegrastim-xnst) injection and fund Spectrum's operations through 2024. The first was a $30 million loan drawn upon closing. The remaining

Yahoo | September 23, 2022

Read More 'SPPI' Stories Here

SPPI Price Returns

1-mo -63.33%
3-mo -47.36%
6-mo -61.40%
1-year -78.00%
3-year -94.17%
5-year -96.92%
YTD -65.35%
2021 -62.76%
2020 -6.32%
2019 -58.40%
2018 -53.83%
2017 327.77%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5687 seconds.